Oncolytic adenovirus-mediated transfer of the antisense chk2 selectively inhibits tumor growth in vitro and in vivo

被引:9
作者
Chen, G. [1 ]
Zhou, J. [1 ]
Gao, Q. [1 ]
Huang, X. [1 ]
Li, K. [1 ]
Zhuang, L. [1 ]
Huang, M. [1 ]
Xu, G. [1 ]
Wang, S. [1 ]
Lu, Y. [1 ]
Ma, D. [1 ]
机构
[1] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Canc Biol Ctr, Wuhan 430030, Hubei, Peoples R China
基金
中国国家自然科学基金;
关键词
cancer; chk2 (checkpoint kinase 2); adenovirus;
D O I
10.1038/sj.cgt.7700967
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Screening and identifying molecules target to checkpoint pathways has fostered the development of checkpoint-based anticancer strategies. Among these targets, inhibition of chk2 may induce cell death for tumors whose growth depends on enhanced chk2 activity. However, improvement of the potency and specificity of such therapeutics remains a major challenge. To resolve this problem, we constructed M3, a novel recombinant adenovirus with a 27-bp deletion in E1A CR2 region by which to realize tumor-specific replication, and an 829-bp of antisense chk2 fragment inserted into the E3 coding region. In this design, M3 exploited the native adenovirus E3 promoters to express antisense chk2 cDNA in a viral replication-dependent fashion, and preferentially silenced the chk2 gene in tumor cells. In vitro and in vivo assays confirmed that downregulated chk2 expression induced by M3 infection was tumor-specific and virus replication-dependent. Furthermore, systemic administration of M3 combined with a low dose of cisplatin cured 75% (9/12) of orthotopic hepatic carcinoma mouse models that were otherwise resistant to cisplatin. Our results indicated that the upcoming development in this field would improve the antitumor efficacy and maximize the synergistic effect of oncolytic viruses administered with traditional chemotherapy or radiotherapy.
引用
收藏
页码:930 / 939
页数:10
相关论文
共 36 条
[1]   Liver metastases from lung cancer [J].
Baron, M ;
Lewis, V .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (03) :180-180
[2]   Chk1 and Chk2 kinases in checkpoint control and cancer [J].
Bartek, J ;
Lukas, J .
CANCER CELL, 2003, 3 (05) :421-429
[3]   An adenovirus mutant that replicates selectively in p53-deficient human tumor cells [J].
Bischoff, JR ;
Kim, DH ;
Williams, A ;
Heise, C ;
Horn, S ;
Muna, M ;
Ng, L ;
Nye, JA ;
SampsonJohannes, A ;
Fattaey, A ;
McCormick, F .
SCIENCE, 1996, 274 (5286) :373-376
[4]   Conditionally replicating adenoviruses expressing short hairpin RNAs silence the expression of a target gene in cancer cells [J].
Carette, JE ;
Overmeer, RM ;
Schagen, FHE ;
Alemany, R ;
Barski, OA ;
Gerritsen, WR ;
van Beusechem, VW .
CANCER RESEARCH, 2004, 64 (08) :2663-2667
[5]   Mammalian Chk2 is a downstream effector of the ATM-dependent DNA damage checkpoint pathway [J].
Chaturvedi, P ;
Eng, WK ;
Zhu, Y ;
Mattern, MR ;
Mishra, R ;
Hurle, MR ;
Zhang, XL ;
Annan, RS ;
Lu, Q ;
Faucette, LF ;
Scott, GF ;
Li, XT ;
Carr, SA ;
Johnson, RK ;
Winkler, JD ;
Zhou, BBS .
ONCOGENE, 1999, 18 (28) :4047-4054
[6]  
Chen Y, 2001, CANCER RES, V61, P5453
[7]   Use of replicating oncolytic adenoviruses in combination therapy for cancer [J].
Chu, RL ;
Post, DE ;
Khuri, FR ;
Van Meir, EG .
CLINICAL CANCER RESEARCH, 2004, 10 (16) :5299-5312
[8]   Intravascular injections of a conditional replicative adenovirus (adl118) prevent metastatic disease in human breast carcinoma xenografts [J].
Fabra, A ;
Parada, C ;
Vinyals, A ;
Duque, PM ;
Fernandez, V ;
Sanchez-Prieto, R ;
Cajal, SRY .
GENE THERAPY, 2001, 8 (21) :1627-1634
[9]  
GARY K, 1999, ISOLATION GROWTH PUR
[10]   E1B-deleted adenovirus (dl1520) gene therapy for patients with primary and secondary liver tumors [J].
Habib, NA ;
Sarraf, CE ;
Mitry, RR ;
Havlík, R ;
Nicholls, J ;
Kelly, M ;
Vernon, GC ;
Gueret-Wardle, D ;
El-Masry, R ;
Salama, H ;
Ahmed, R ;
Michail, N ;
Edward, E ;
Jensen, SL .
HUMAN GENE THERAPY, 2001, 12 (03) :219-226